male sexual function
Conditions
Interventions
34 patients will receive duloxetine then placebo in group A
34 patients will receive placebo then duloxetine in group B
Sponsors
Kasr AlAiny faculty of medicine
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Male patients with PE (primary or secondary) with stable and committed relationship having (IELT) < 2 minutes were included
Exclusion criteria
Exclusion criteria: Patients with erectile dysfunction (ED), reduced sexual desire or inhibited male orgasm or active genitourinary tract infection (confirmed by two glasses of urine and EPS) or known mental disorders (Depression, Anxiety, Schizophrenia) or uncontrolled physical illnesses (Hepatic, Renal, Cardiac, Neurological, Endocrinal) were excluded from the study. Finally, any alcohol or drug abuser or patient with known hypersensitivity to duloxetine was excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| improvement in premature ejaculation | — |
Secondary
| Measure | Time frame |
|---|---|
| impact on sexual function and quality of life | — |
Countries
Africa
Contacts
Public Contactsameh gamalel din
Kasr AlAiny faculty of medicine Andrology & STDs
Outcome results
None listed